Second anticancer CAR T therapy receives FDA approval
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Animal-derived and human-derived components, such as serum and growth factors, carry a higher risk of virus contamination than other media components and are commonly added to media for ATMP production.
“Animalderived (Table 2) and human-derived components (e.g., serum, growth factors), which carry a higher risk of virus contamination than other media components 47 , are commonly added to media for ATMP production 48 .”
From Viral contamination in biologic manufacture and implications for emerging therapies (2020) · cites this paper as [48]
Cited by
Sorted by citations
Viral contamination in biologic manufacture and implications for emerging therapies
Barone, P. W., Wiebe, M. E., Leung, J. C., Hussein, I. T. M., Keumurian, F. J., Bouressa, J., Brussel, A., Chen, D., Chong, M., Dehghani, H., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0507-2 · Cited by 212 · see citing works
Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics
Panch, S. R., Srivastava, S. K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S. L., Li, X., Dagur, P., Kochenderfer, J. N., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.015 · Cited by 107 · see citing works
- Authors
- Mullard, A.
- Corresponding author
- Mullard, Asher
- Venue
- Nature Reviews Drug Discovery
- Published
- 2017-11-28
- Volume
- 16
- Issue
- 12
- Pages
- 818-818
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2768404466
- Cited by
- 34
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 10 · 2019: 5 · 2018: 6
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, axicabtagene ciloleucel, tisagenlecleucel, FDA approval, large B-cell lymphoma, relapsed/refractory lymphoma, acute lymphoblastic leukemia, chimeric antigen receptor, Gilead Sciences, Novartis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
